Bastiano Sanna - 04 Apr 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
04 Apr 2022
Net transactions value
-$1,021,004
Form type
4
Filing time
06 Apr 2022, 17:02:38 UTC
Previous filing
05 Apr 2022
Next filing
08 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $81,466 -305 -0.65% $267.10 46,763 04 Apr 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale $68,987 -257 -0.55% $268.43 46,506 04 Apr 2022 Direct F1, F2, F4
transaction VRTX Common Stock Sale $870,552 -3,163 -6.8% $275.23 43,343 05 Apr 2022 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F2 Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $267.10 (range $266.66 to $267.57).
F4 Open market sales reported on this line occurred at a weighted average price of $268.43 (range $267.81 to $268.78).
F5 Open market sales reported on this line occurred at a weighted average price of $275.23 (range $275.00 to $275.66).